Literature DB >> 30403305

Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.

Christopher M Bland1, Manjunath P Pai2, Thomas P Lodise3.   

Abstract

Therapeutic drug management is regularly performed for aminoglycosides in an effort to maximize their effectiveness and safety. The ratio of maximum plasma drug concentration to minimum inhibitory concentration (Cmax/MIC) has long been regarded as the primary pharmacokinetic/pharmacodynamic (PK/PD) index of clinical efficacy for aminoglycosides due to their concentration-dependent killing. In this review, however, we discuss why the area under the plasma concentration-time curve (AUC)/MIC ratio may be a more reliable indicator of bacterial killing and clinical efficacy for these agents. The definitive AUC/MIC efficacy targets for aminoglycosides are less clear, unlike those that exist for fluoroquinolones. Evaluation of available literature suggests that an AUC/MIC ratio of 30-50 for aminoglycoside therapy may provide optimal outcomes when targeting non-critically ill immunocompetent patients with low-bacterial burden gram-negative infections such as urinary tract infections or in patients receiving additional gram-negative therapy with good source control. However, an AUC/MIC target of 80-100 may be more prudent when treating patients with aminoglycoside monotherapy or in critically ill patients with high-bacterial burden infections, such as nosocomial pneumonia. Reappraisal of current antimicrobial susceptibility breakpoints for aminoglycosides against gram-negative bacteria may also be necessary to achieve these AUC/MIC targets and ensure that current empiric doses are not grossly suboptimal in critically ill patients. Although it has been historically difficult to calculate AUCs in clinical practice, equation-based and Bayesian approaches now can be used to estimate the AUC in clinical practice, with limited PK sampling. Additional research is needed to better define optimal AUC/MIC targets for efficacy, especially when drugs are used in combination, as well as PK/PD targets associated with suppression of resistance. It is also important to determine if AUC can predict nephrotoxicity of these agents or whether trough concentrations should be used instead.
© 2018 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  AUC/MIC; PK/PD; aminoglycosides; critical illness; pharmacodynamics; pharmacokinetics; therapeutic drug management

Mesh:

Substances:

Year:  2018        PMID: 30403305     DOI: 10.1002/phar.2193

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.

Authors:  Clément Boidin; Laurent Bourguignon; Sabine Cohen; Claire Roger; Jean-Yves Lefrant; Jason A Roberts; Bernard Allaouchiche; Alain Lepape; Arnaud Friggeri; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model.

Authors:  Iris H Chen; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

3.  Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model.

Authors:  Katrina Chan; Kimberly R Ledesma; Weiqun Wang; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 4.  Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.

Authors:  Andrew Chou; Elwyn Welch; Andrew Hunter; Barbara W Trautner
Journal:  Drugs       Date:  2022-03-14       Impact factor: 11.431

5.  Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.

Authors:  Cédric Carrié; Faustine Delzor; Stéphanie Roure; Vincent Dubuisson; Laurent Petit; Mathieu Molimard; Dominique Breilh; Matthieu Biais
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6')-Ib.

Authors:  David A Butler; Amisha P Rana; Fiorella Krapp; Shitalben R Patel; Yanqin Huang; Egon A Ozer; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

Review 7.  Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?

Authors:  Alexandre Duong; Chantale Simard; Yi Le Wang; David Williamson; Amélie Marsot
Journal:  Antibiotics (Basel)       Date:  2021-04-29

8.  Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis.

Authors:  Jennifer Le; Rachel G Greenberg; Daniel K Benjamin; YoungJun Yoo; Kanecia O Zimmerman; Michael Cohen-Wolkowiez; Kelly C Wade
Journal:  J Pediatric Infect Dis Soc       Date:  2021-05-28       Impact factor: 5.235

9.  Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.

Authors:  Antonin Praet; Laurent Bourguignon; Florence Vetele; Valentine Breant; Charlotte Genestet; Oana Dumitrescu; Anne Doleans-Jordheim; Philippe Reix; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

10.  Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease.

Authors:  Xuanyou Jin; Jaeseong Oh; Joo-Youn Cho; SeungHwan Lee; Su-Jin Rhee
Journal:  Antibiotics (Basel)       Date:  2020-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.